ABSTRACT: Infliximab is a TNFα inhibiting recombinant monoclonal antibody, which provides an efficient therapeutic opportunity in the treatment of psoriasis and other immune-mediated inflammatory diseases. It is well tolerated and improves quality of life significantly. The authors present a case of drug-induced lupus erythematosus as a possible side effect of this medication.
The patient developed psoriasis 9 years ago when she was on beta-receptor blocker therapy.
The symptoms deteriorated despite topical and systemic treatments and, therefore, biological therapy was introduced. In the third year of treatment drug-induced lupus erythematosus was diagnosed on the background of general symptoms.
After cessation of the biologic treatment a low dose corticosteroid therapy was introduced which proved to be effective. Symptoms as well as pathological laboratory parameters showed an improvement.
Leírás: Patients will receive 1 subcutaneous SC injection of FYB at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses. Karcsoport címke: FYB Proposed ustekinumab biosimilar Beavatkozás típusa: Drug Beavatkozás neve: Stelara® Ustekinumab Leírás: Patients will receive 1 subcutaneous SC injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses. Patients who provided written informed consent and who are able to complete study procedures. Patients who are at least 18 years of age at time of screening.
The authors conclude that biologicals are effective and safe in the treatment of psoriasis, nevertheless, they have risks too. To psoriasis treatment 2020 side effects a meticulous follow-up of patients is essential.
Psoriasis Treatment - Explained by Dermatologist
Any general symptom requires careful examination since they might be linked to serious side effects of the biological therapy.